These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3906944)

  • 1. Gonadotrophin-releasing hormone analogue agonists--a new approach in advanced prostatic cancer.
    Thürlimann BJ; Falkson G
    S Afr Med J; 1985 Dec; 68(12):888-9. PubMed ID: 3906944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
    Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
    Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Surgical or medical castration with LH-RH analogue for prostatic cancer].
    Kameyama S; Yamazaki S; Kitamura T
    Nihon Rinsho; 1998 Aug; 56(8):2114-8. PubMed ID: 9750518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment.
    Wenderoth UK; Jacobi GH
    Prog Clin Biol Res; 1985; 185A():297-305. PubMed ID: 3162176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotrophin releasing hormone analogues for advanced prostate cancer.
    Drug Ther Bull; 1992 Aug; 30(17):65-7. PubMed ID: 1396111
    [No Abstract]   [Full Text] [Related]  

  • 6. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of a long acting luteinizing hormone releasing hormone agonist (Decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Preliminary report.
    De Sy WA; de Meyer JM; Casselman J; De Smet R; Renders G; Schelfhout W; De Wilde P
    Acta Urol Belg; 1986; 54(2):221-9. PubMed ID: 2942015
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
    Santen RJ; Warner B
    Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Histrelin acetate--the first once yearly LHRH agonist].
    Altarac S
    Lijec Vjesn; 2011; 133(9-10):320-2. PubMed ID: 22165080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Luteinizing hormone-releasing hormone agonists for treatment of prostatic cancer].
    Gez E
    Harefuah; 1990 Apr; 118(8):483-6. PubMed ID: 2192959
    [No Abstract]   [Full Text] [Related]  

  • 12. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical development of nafarelin acetate. Phase I and phase II studies.
    Hoffman PG; Henzl MR; Chaplin MD; Nerenberg CA
    J Androl; 1987; 8(1):S17-22. PubMed ID: 2951357
    [No Abstract]   [Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone agonists. Current uses for these increasingly important drugs.
    Winkel CA
    Postgrad Med; 1994 May; 95(6):111-8. PubMed ID: 8170869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The treatment of prostatic cancer by LH-RH agonist.
    Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetsu I
    Prog Clin Biol Res; 1987; 243A():429-34. PubMed ID: 3116552
    [No Abstract]   [Full Text] [Related]  

  • 16. [LH-RH treatment of patients with prostatic cancer by subcutaneous injection, non-biodegradable and biodegradable slow delivery system and intranasal spray application].
    Imai K; Saruki K; Totsuka Y; Shimizu N; Yamanaka H; Kitaura K; Tomaru Y; Nakamura T; Koya A; Yazima H
    Nihon Hinyokika Gakkai Zasshi; 1987 Mar; 78(3):411-9. PubMed ID: 3116307
    [No Abstract]   [Full Text] [Related]  

  • 17. [Gonadotrophin releasing hormone analogues in prostatic cancer: can we consider them truly equivalent?].
    Alcaraz Asensio A
    Actas Urol Esp; 2013 Apr; 37(4):193-8. PubMed ID: 23510678
    [No Abstract]   [Full Text] [Related]  

  • 18. [The use of agonist analogues of luteinizing hormone--releasing hormone in the treatment of prostatic carcinoma].
    Gez E; Ben-Yosef R; Libson E; Biran S
    Harefuah; 1987 Mar; 112(5):239-41. PubMed ID: 3301586
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
    Nillius SJ; Bergquist C; Wide L
    Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.